Trial · NCT03148756
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Clinical Response at Day 84 in the Intent-to Treat (ITT) Population | Day 84 | ITT Population included all randomized participants regardless of whether or not study treatment was received. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have an early termination visit. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Participants With Clinical Outcome of Success at Day 42 in the ITT Population | Day 42 | ITT Population included all randomized participants regardless of whether or not study treatment was received. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have an early termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Outcome of Success at Day 42 in the Clinically Evaluable (CE) Population | Day 42 | CE Population included all participants in the mITT Population (all in the ITT who received ≥1 dose of study treatment) who met criteria for clinical evaluability. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have a termination visit. | percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Day 84 Mortality in the Safety Population | Day 84 | Safety Population included all randomized participants who received at least 1 dose of study treatment. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have an early termination visit. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Participants With Clinical Outcome of Success at Day 84 in the CE Population | Day 84 | CE Population included all participants in the mITT Population (all in the ITT who received ≥1 dose of study treatment) who met criteria for clinical evaluability. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have a termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the ITT Population | Day 42 | ITT Population included all randomized participants regardless of whether or not study treatment was received. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have an early termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the ITT Population | Day 84 | ITT Population included all randomized participants regardless of whether or not study treatment was received. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have an early termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 42 in the CE Population | Day 42 | CE Population included all participants in the mITT Population (all in the ITT who received ≥1 dose of study treatment) who met criteria for clinical evaluability. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have a termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Outcome of Success by Pathogen at Day 84 in the CE Population | Day 84 | CE Population included all participants in the mITT Population (all in the ITT who received ≥1 dose of study treatment) who met criteria for clinical evaluability. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have a termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the ITT Population | Day 42 | ITT Population included all randomized participants regardless of whether or not study treatment was received. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have an early termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the ITT Population | Day 84 | ITT Population included all randomized participants regardless of whether or not study treatment was received. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have an early termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Success by Pathogen at Day 42 in the CE Population | Day 42 | CE Population included all participants in the mITT Population (all in the ITT who received ≥1 dose of study treatment) who met criteria for clinical evaluability. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have a termination visit. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Microbiological Success by Pathogen at Day 84 in the CE Population | Day 84 | CE Population included all participants in the mITT Population (all in the ITT who received ≥1 dose of study treatment) who met criteria for clinical evaluability. No participants were enrolled in the Dalbavancin arm. Due to early termination of the study, 1 participant did not have clinical outcomes determined, but did have a termination visit. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03148756/outcomes